PatentMay 12, 2026, 08:34 AM
Akari Therapeutics Secures Major European Patent for PH1 ADC Platform
AI Summary
Akari Therapeutics announced the grant of a major European patent (No. 3684773B1) for its proprietary Thailanstatin-based PH1 ADC payload platform. This patent provides broad composition-of-matter protection across numerous European countries, significantly strengthening the company's global intellectual property. The patent reinforces Akari's ability to develop a differentiated antibody-drug conjugate (ADC) pipeline, including lead candidate AKTX-101, which is in IND-enabling studies with a Phase 1 trial expected by mid-2027.
Key Highlights
- Major European Patent No. 3684773B1 granted for Akari's Thailanstatin Analogs.
- Patent provides broad composition-of-matter protection for the proprietary PH1 ADC payload platform.
- Protection extends across 30+ European countries, including Germany, France, and the UK.
- Strengthens global IP portfolio, which includes patents in US, China, Japan, Australia, India, Mexico, Israel.
- Lead candidate AKTX-101 (TROP2-targeting ADC) is in IND-enabling studies.
- Phase 1 first-in-human clinical trial for AKTX-101 expected by mid-2027.
- Developing AKTX-102 targeting CEACAM5, leveraging the PH1 spliceosome-modulating payload.
Price Impact
More from AKTX